



(12) Translation of new
European patent specification
After opposition procedure

(11) NO/EP 2219647 B2

NORWAY (19) NO
(51) Int Cl.

A61K 31/495 (2006.01)
A61P 25/00 (2006.01)

Norwegian Industrial Property Office

(45) Translation Published 2012.04.23

(80) Date of The European Patent Office Publication of the Granted Patent 2011.12.21

(45) Decision of the opposition in EPO 2020.07.29

Decision of the opposition in NIPO 2020.10.26

(86) European Application Nr. 08850935.1

(86) European Filing Date 2008.11.12

(87) The European Application's Publication Date 2010.08.25

(30) Priority 2007.11.13, DK, 200701607
2007.12.14, DK, 200701788
2008.09.17, DK, 200801300
2007.11.13, US, 987710 P
2007.12.14, US, 13722
2008.09.17, US, 97840

(84) Designated Contracting States: AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MT ; NL ; NO ; PL ; PT ; RO ; SE ; SI ; SK ; TR

Designated Extension States: AL ; BA ; MK ; RS

(73) Proprietor H. Lundbeck A/S, Ottiliavej 9, 2500 Valby, Danmark
Takeda Pharmaceuticals U.S.A., Inc., One Takeda Parkway, Deerfield, IL 60015, USA

(72) Inventor MOORE, Nicholas, 220 N. Pleasant Avenue, Ridgewood, NJ 07450, USA
DRAGHEIM, Marianne, Trolldager 2, DK-2950 Vedbæk, Danmark
CHON, Jin, 412 South Cook Street, Barrington, Illinois 60010, USA
BATRA, Aneil, 4040 N Mozart Street Unit 3, Chicago, Illinois 60618, USA

(74) Agent or Attorney BRYN AARFLOT AS, Stortingsgata 8, 0161 OSLO, Norge

(54) Title **Terapeutiske anvendelser av forbindelser som har kombinert sert, 5-HT3 og 5-HT1A aktivitet**

(56) References Cited: WO-A-03/029232
WO-A-2007/144005
WO-A1-2007/144005

WO-A2-2008/113359

WO-A1-03/029232

WO-A-2008/113359

De Battista et al: Biological psychiatry, vol. 44, no. 5, 1998, page 341,

Gregorian, R. et al: The Annals of Pharmacotherapy, vol. 36, 2002, pages 155-159,

Curriculum Vitae for Dr Parmentier

Guidelines for Phase I Clinical Trials, The Association of the British Pharmaceutical Industry, London, 2007 Edition

Margolese, H. et al: Journal of sex & marital therapy, vol. 22, no. 3, 1996, pages 210-219

Serretti, A. et al: J Clin Psychopharmacol., vol. 29, no. 3, pages 256-266,

Worthington II et al: Drugs of Today, vol. 39, no. 11, 2003, page 887,

Dharshaktu et al: J Clin. Pharmacol, vol. 52, no. 6, 2012,

Westenberg and Sandner: Int J Clin Pract., vol. 60, 2006, page 482,

Taylor et al: The Maudsley Prescribing Guidelines, Informa Healthcare, 9th Ed., 2007, page 231-234,

Buoen, C. et al: J. Clin. Pharmacol., vol. 45, 2005, pages 1123-1136,

Anttila, S. et al: CNS Drug Reviews, vol. 7, no. 3, 2001, pages 249-264,

Harvey, K. et al: Annals of Clinical Psychiatry, vol. 7, no. 4, 1995, pages 189-201,

Baldwin et al: J Clin. Psychiatry, vol. 67, no. sup 6, 2006, page 9,

Stahl: Int J Psychiatry in Clin. Practice, vol. 8, no. 3, 2004,

Fava et al: Expert Rev Neurotherapeutics, vol. 6, no. 11, 2006, page 1735,

Rothschild, A. J.: Clin. Ther., vol. 22, no. sup A, 2000, page A42,

FDA approved labelling for sertraline (Zoloft) action date 14.09.2006

Declaration of Professor Hans-Peter Volz

Preskorn, S. H. et al: Antidepressants: Past, Present and Future, vol. 157, 2004, pages 250-252,

Khawam et al: Cleveland Clinic journal of medicine, vol. 73, no. 4, 2006, page 351,

Baldwin et al: Europ. Neuropsychopharm, vol. 22, 2012, page 482,

Antai-Otong, D.: Perspect. Psychiatr. C., vol. 40, no. 1, 2004, page 29,

Alvarez, E. et al: Int. J. Neuropsychoph., vol. 15, 2012, pages 589-600,

FDA approved labelling for fluoxetine (Prozac) capsules and oral solution; action date 20.09.2006

Katona, C. et al: Int. Clin. Psychopharm., vol. 27, 2012, pages 215-223,

Moltzen and Bang-Andersen: Cuff Topic Med Chem, vol. 6, no. 17, 2006, page 1801,

Alvarez et al: Int J Neuropsychopharmacol, vol. 15, no. 5, 2012, page 589,

Declaration of Dr Henk Parmentier

Vissers, K. et al: Pharmacol. Biochem. Be., vol. 84, 2006, pages 479-486,

NCDEU Annual Meeting; 31 May 2013, Hollywood, FL, USA

Statement on a nonproprietary name adopted by the USAN council

Assessment report for an initial marketing authorisation, European Medicines Agency,

24.10.2013 (as published 14.01.2014)

Correll, C. U., Medscape (online article) (2013)

Ashton: Journal of sex & marital therapy, vol. 30, no. 1, 2004, page 1,

Spinks and Spinks: Cuff Med Chem, vol. 9, 2002, page 799,

Baron: Dtsch Arztebl, vol. 103, no. 41, 2006, page A 2720,

To et al: BCMJ, vol. 44, no. 79, 2002,

Curriculum Vitae for Prof. Volz

Fava et al: J. Clin. Psychiatry, vol. 63, no. sup 5, 2002, page 13,

Ruhe et al: The journal of clinical psychiatry, vol. 67, no. 12, 2006, page 1836,

MEALY N E ET AL: "Lu-31-130/Lu-AA-21004/Lu-35-138" DRUGS OF THE FUTURE 200409 ES, vol. 29, no. 9, September 2004 (2004 -09), pages 954-955, XP009110475 ISSN: 0377 -8282

LARSEN KARI: "Lundbeck says antidepressant LuAA21004 positive in phase II - shares jump" INTERNET ARTICLE, [Online] 2 October 2007 (2007 -10-02), XP002509653 Retrieved from the Internet: URL:<http://health.apmnews.com/depechesPubl>

ieesDepeches.php?annee=2007&mois=10&jour=2 > [retrieved on 2009-01-08]

Iyengar, S. et al: J. Pharmacol. Exp. Ther., vol. 311, no. 2, 2004, page 576,

Anderson et al: J Psychopharmacol, vol. 22, no. 4, 2008, page 343,

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Anvendelse av 1-[2-(2,4-dimetylfenylsulfanyl)-fenyl]piperazin og farmasøytisk akseptable salter derav i fremstillingen av et medikament for behandlingen av en sykdom valgt fra depresjon, angst, misbruk eller kronisk smerte, hvor nevnte medikament er for anvendelse i en pasient som tidligere mottok en annen medisinerings for behandlingen av nevnte sykdom hvor medisinerings ble avsluttet eller redusert på grunn av søvnrelaterte negative hendelser.
5
2. Anvendelse ifølge krav 1, hvor nevnte farmasøytisk akseptable salt er hydrobromidsalt.
10
3. 1-[2-(2,4-dimetylfenylsulfanyl)-fenyl]piperazin og farmasøytisk akseptable salter derav for anvendelse i behandlingen av en sykdom valgt fra depresjon, angst, misbruk eller kronisk smerte, hvor nevnte medikament er for anvendelse i en pasient som tidligere mottok en annen medisinerings for behandlingen av nevnte sykdom hvor medisinerings ble avsluttet eller redusert på grunn av søvnrelaterte negative hendelser.
15
4. 1-[2-(2,4-dimetylfenylsulfanyl)-fenyl]piperazin og farmasøytisk akseptable salter for anvendelse ifølge krav 3, som er hydrobromidsaltet.